Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Allakos Inc. ALLK

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.


Recent & Breaking News (NDAQ:ALLK)

Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock

GlobeNewswire 10 days ago

Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)

GlobeNewswire September 12, 2022

Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis

GlobeNewswire September 9, 2022

Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results

GlobeNewswire August 4, 2022

Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors

GlobeNewswire July 25, 2022

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.- ALLK

Newsfile June 15, 2022

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.- ALLK

Newsfile June 14, 2022

INVESTIGATION NOTICE: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.- ALLK

Newsfile June 13, 2022

INVESTIGATION REMINDER: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.- ALLK

Business Wire June 10, 2022

INVESTIGATION ALERT: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.- ALLK

Business Wire June 9, 2022

Allakos Provides Business Update and Reports First Quarter 2022 Financial Results

GlobeNewswire May 6, 2022

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire March 1, 2022

Allakos to Host Investor Day on February 15

GlobeNewswire February 1, 2022

Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases

GlobeNewswire December 21, 2021

Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma

GlobeNewswire November 30, 2021

Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results

GlobeNewswire November 8, 2021

Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic Evaluation

GlobeNewswire October 25, 2021

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting

GlobeNewswire October 24, 2021

Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results

GlobeNewswire August 9, 2021

Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)

GlobeNewswire June 7, 2021